Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

New England Journal of Medicine, Journal Year: 2019, Volume and Issue: 381(21), P. 2020 - 2031

Published: Sept. 28, 2019

In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the response rate was better nivolumab plus ipilimumab than monotherapy, particularly among tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess long-term benefit of in NSCLC.

Language: Английский

---

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

Cellular and Molecular Immunology, Journal Year: 2020, Volume and Issue: 17(8), P. 807 - 821

Published: July 1, 2020

Abstract Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types immunotherapy, including adoptive cell transfer (ACT) immune checkpoint inhibitors (ICIs), have obtained durable clinical responses, but their efficacies vary, only subsets patients can benefit from them. Immune infiltrates in microenvironment (TME) been shown to play a key role development will affect outcomes patients. Comprehensive profiling tumor-infiltrating cells would shed light on mechanisms cancer–immune evasion, thus providing opportunities for novel therapeutic strategies. However, highly heterogeneous dynamic nature TME impedes precise dissection intratumoral cells. With recent advances single-cell technologies such as RNA sequencing (scRNA-seq) mass cytometry, systematic interrogation is feasible provide insights into functional diversities In this review, we outline progress particularly by focusing landmark studies characterization tumor-associated cells, summarize phenotypic connections with immunotherapy. We believe review could strengthen our understanding facilitate elucidation modulation progression, guide immunotherapies treatment.

Language: Английский

---

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

Annual Review of Pathology Mechanisms of Disease, Journal Year: 2020, Volume and Issue: 16(1), P. 223 - 249

Published: Nov. 16, 2020

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer immunotherapy. Starting with approval anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA-4) for advanced-stage melanoma 2011, ICIs-which now also include antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1)-quickly gained US Food Drug Administration treatment a wide array types, demonstrating unprecedented extension patient survival. However, despite success ICIs, resistance to these agents restricts number patients able achieve durable responses, immune-related adverse events complicate treatment. Thus, better understanding requirements effective safe antitumor immune response following ICI therapy is needed. Studies both tumoral systemic changes system yielded insight into basis efficacy resistance. Ultimately, by building on insights, researchers should be combine ICIs other agents, or design new immunotherapies, broader more as well greater safety. Here, we review history clinical utility mechanisms therapy, local associated outcome.

Language: Английский

---

Tumor microenvironment as a therapeutic target in cancer

Pharmacology & Therapeutics, Journal Year: 2020, Volume and Issue: 221, P. 107753 - 107753

Published: Nov. 28, 2020

Language: Английский

---

Tumour-intrinsic resistance to immune checkpoint blockade

Nature reviews. Immunology, Journal Year: 2019, Volume and Issue: 20(1), P. 25 - 39

Published: Sept. 30, 2019

Language: Английский

---

Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy

Cancer Letters, Journal Year: 2019, Volume and Issue: 470, P. 126 - 133

Published: Nov. 13, 2019

Language: Английский

---

CD8+ T cell states in human cancer: insights from single-cell analysis

Nature reviews. Cancer, Journal Year: 2020, Volume and Issue: 20(4), P. 218 - 232

Published: Feb. 5, 2020

Language: Английский

---

Systemic immunity in cancer

Nature reviews. Cancer, Journal Year: 2021, Volume and Issue: 21(6), P. 345 - 359

Published: April 9, 2021

Language: Английский

---

Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion

Nature Biotechnology, Journal Year: 2019, Volume and Issue: 37(8), P. 925 - 936

Published: Aug. 1, 2019

Language: Английский

---

Neoadjuvant checkpoint blockade for cancer immunotherapy

Science, Journal Year: 2020, Volume and Issue: 367(6477)

Published: Jan. 31, 2020

Presurgical immune checkpoint blockade Checkpoint immunotherapy using antibodies that inhibit the programmed cell death 1 (PD-1) or cytotoxic T lymphocyte–associated protein 4 (CTLA-4) pathways has resulted in unprecedented clinical outcomes for certain cancers such as melanoma. Topalian et al. review advances neoadjuvant (presurgical) an important next step enhancing response of early-stage tumors to blockade. They highlight mechanistic rationale and recent trials based on anti–PD-1 ligand (anti–PD-L1) therapy. Pathological assessment criteria may provide early on-treatment biomarkers predict patient are also discussed. Science , this issue p. eaax0182

Language: Английский

---